Claims for Patent: 7,273,928

Summary for Patent: 7,273,928

Title:	Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin
Abstract:	A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.
Inventor(s):	Markl; Jurgen (Gau-Bischofsheim, DE), Altenhein; Benjamin (Wiesbaden, DE), Lieb; Bernard (Mainz, DE), Stiefel; Thomas (Stuttgart, DE)
Assignee:	Biosyn Arzneimittel GmbH (Fellbach, DE)
Application Number:	11/512,044
Patent Claims:	1. An isolated nucleic acid molecule comprising a nucleic acid sequence that codes for a Keyhole Limpit Hemocyanin 2 (KLH2) polypeptide and comprises at least one intron sequence, wherein said nucleic acid sequence is selected from the group consisting of, (a) a DNA sequence or the corresponding RNA sequence selected from the group consisting of: SEQ ID NO:20 (KLH2 domain b), SEQ ID NO:21 (KLH2 domain c), SEQ ID NO:22 (partial KLH2 domain d), SEQ ID NO:23 (KLH2 domain g), SEQ ID NO:24 (partial KLH2 domain h), SEQ ID NO:57 (KLH2 domain b'), SEQ ID NO:58 (KLH2 domain c'), SEQ ID NO:59 (KLH2 domain d'), SEQ ID NO:60 (KLH2 domain e), SEQ ID NO:61 (KLH2 domain f), SEQ ID NO:62 (KLH2 domain g'), SEQ ID NO:102 (KLH2 domain b''), SEQ ID NO:103 (KLH2 domain c''), SEQ ID NO:104 (KLH2 domain d''), SEQ ID NO:105 (KLH2 domain e''), SEQ ID NO:106 (KLH2 domain f''), SEQ ID NO:107 (KLH2 domain g''); and, SEQ ID NO:108 (partial KLH2 domain h''), (b) a nucleic acid sequence that hybridizes under stringent hybridization conditions of 0.55.times.SSC; 1% blocking reagent; 0.1% sodium dodecyl sulfate (SDS) at about 68.degree. C. overnight, to a counter-strand of a nucleic acid sequence according to (a); and (c) a nucleic-acid sequence that has at least 90% sequence identity to one of the nucleic acid sequences described under (a). 2. The isolated nucleic acid molecule according to claim 1, wherein the intron sequence is selected from: (i) a DNA sequencer the corresponding RNA sequence selected from the group consisting of: SEQ ID NO:147 (KLH2 intron 2B/2C), SEQ ID NO:148 (KLH2 intron 2C/2D), SEQ ID NO:149 (KLH2 intron 2D/2E), SEQ ID NO:150 (KLH2 intron 2E/2F), SEQ ID NO:151 (KLH2 intron 2F), SEQ ID NO:152 (KLH2 intron 2F-2/2G), SEQ ID NO:153 (KLH2 intron 2G-1/2G-2), SEQ ID NO:154 (KLH2 intron 2G-2/2G-3), and SEQ ID NO:155 (KLH2 intron 2G/2H); (ii) a nucleic acid sequence that hybridizes under stringent conditions with the counter-strand of a nucleic acid sequence according to (i); (iii) a nucleic acid sequence that has at least 90% sequence identity to one of the nucleic acid sequences described under (i); and (iv) combinations of several of the DNA sequences described under (i) to (iii). 3. The isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule described under (b) has at least 95% identity to a nucleic acid sequence described under (a). 4. The isolated nucleic acid molecule according to claim 2, wherein the nucleic acid molecule described under (iii) has at least 95% identity to one of the nucleic acid sequence described under (i). 5. The isolated nucleic acid molecule according to claim 1 that is a deoxyribonucleic acid molecule. 6. A process for the preparation of a KLH2 haemocyanin polypeptide, wherein the nucleic acid molecule according to claim 1 is expressed in a suitable host cell and the protein is isolated. 7. The process according to claim 6, wherein the KLH2 haemocyanin polypeptide prepared is modified naturally or chemically. 8. The process according to claim 7, wherein the modification is cross-linking or covalent bonding to an antigen. 9. The process according to claim 6, wherein the expression is carried out in a host cell is a prokaryotic or eukaryotic cell suitable for expression of the construct. 10. A composition comprising a nucleic acid molecule having a sequence according to claim 1. 11. A construct comprising a nucleic acid molecule sequence that codes for a Keyhole Limpit Hemocyanin 2 (KLH2) polypeptide and comprises at least one intron sequence wherein said nucleic acid sequence is selected from the group consisting of: (a) a DNA sequence or the corresponding RNA sequence selected from the group consisting of: SEQ ID NO:20 (KLH2 domain b), SEQ ID NO:21 (KLH2 domain c), SEQ ID NO:22 (partial KLH2 domain d), SEQ ID NO:23 (KLH2 domain g), SEQ ID NO:24 (partial KLH2 domain h), SEQ ID NO:57 (KLH2 domain b'), SEQ ID NO:58 (KLH2 domain c'), SEQ ID NO:59 (KLH2 domain d'), SEQ ID NO:60 (KLH2 domain e), SEQ ID NO:61 (KLH2 domain f), SEQ ID NO:62 (KLH2 domain g'), SEQ ID NO:102 (KLH2 domain b''), SEQ ID NO:103 (KLH2 domain c''), SEQ ID NO:104 (KLH2 domain d''), SEQ ID NO:105 (KLH2 domain e''), SEQ ID NO:106 (KLH2 domain f''), SEQ ID NO:107 (KLH2 domain g''), and SEQ ID NO:108 (partial KLH2 domain h''); (b) a nucleic acid sequence that hybridizes under stringent hybridization conditions of 0.55.times.SSC; 1% blocking reagent; 0.1% sodium dodecyl sulfate (SDS) at about 68.degree. C. overnight, to a counter-strand of a nucleic acid sequence according to (a); and (c) a nucleic-acid sequence that has at least 90% sequence identity to one of the nucleic acid sequences described under (a) (d) a combination of the DNA sequences described under (a) to (c). 12. The construct according to claim 11, further comprising a promoter suitable for expression control, the nucleic acid sequence that codes for a KLH2 polypeptide being under the control of the promoter. 13. The construct according to claim 11, further comprising a nucleic acid sequence that codes for an antigen and is coupled directly to the nucleic acid sequence that codes for a KLH2 polypeptide. 14. The construct according to claim 13, wherein the antigen is selected from the group consisting of: a tumour antigens, a virus antigens and an antigens of a bacterial or parasitic pathogen. 15. The construct according to claim 11, wherein the construct comprises at least a part of a vector, the vector being selected from the group consisting of: a bacteriophag, an adenovirus, a vaccinia virus, a baculovirus, SV40 virus and a retrovirus. 16. The construct according to claim 11, wherein the construct further comprises a H is tag-coding nucleic acid sequence and the expression of the construct forms a fusion protein with a H is tag. 17. A isolated host cell containing a construct according to claim 11, wherein the host cell is a prokaryotic or eukaryotic cell suitable for expression of the construct. 18. The host cell according to claim 17, wherein the prokaryotic host cell is selected from E. coli and Bacillus subtilis. 19. The host cell according to claim 17, wherein the eukaryotic host cell is selected from the group consisting of a yeast cell, a plant cell, an insect cell and a mammalian cell. 20. The host cell according to claim 19, wherein the host cell is a CHO cell, a COS cell or a HeLa cell. 21. A process for the preparation of a KLH2 haemocyanin polypeptide, wherein the construct-according to claim 11 is expressed in a suitable host cell and the protein is isolated.

Details for Patent 7,273,928

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-08-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-08-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-08-20